Barbara Murphy, MD Email Barbara Murphy
-
- Positions
- DEAN FOR CLINICAL INTEGRATION AND POPULATION HEALTH
- PROFESSOR AND SYSTEM CHAIR | Medicine, Nephrology
-
- Specialties
- Kidney / Pancreas Transplantation
- Nephrology
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
Barbara Murphy, MD is the Murray M. Rosenberg Professor of Medicine, Chair of the Department of Medicine for the Mount Sinai Health System and Dean for Clinical Integration and Population Health. Her area of interest is transplant immunology, focusing on the use of high throughput genomic technologies as a means to understand the immune mechanisms that lead to graft injury and loss, with the aim of identifying gene expression profiles and or genetic variants that may be used to predict those at greatest risk.
Dr. Murphy earned her M.B. B.A.O. B.Ch. from The Royal College of Surgeons in Ireland and went on to do an internship at Beaumont Hospital in Dublin. She completed a residency rotation at Beaumont Hospital followed by a fellowship in Clinical Nephrology also at Beaumont Hospital. Dr. Murphy completed her postdoctoral training with a fellowship in Nephrology at Brigham and Women's Hospital, Harvard Medical School. As part of this she trained in transplant immunology at the Laboratory of Immunogenetics and Transplantation, Renal Division, Brigham and Women's Hospital, Harvard Medical School. Among her many honors, Dr. Murphy was awarded the Young Investigator Award in Basic Science by the American Society of Transplantation in 2003. In 2005, Dr. Murphy was awarded the Irene and Dr. Arthur M. Fishberg Professor of Medicine at The Mount Sinai Hospital. Then, in 2011, she was named Nephrologist of the Year by the American Kidney Fund. She received the distinguished Jacobi Medallion in 2014. She also received an honorary degree from University College, Dublin, Ireland. In 2016, Dr. Murphy was honored by The Annual Irish America Healthcare & Life Science 50. In 2018, she was honored as a ” 2018 Notable Women in Health Care” by Crain’s New York and received an Honorary Doctorate from Royal Colleges of Surgeons in Ireland.
Dr. Murphy belongs to a number of professional societies including the American Society of Transplantation and the American Society of Nephrology. Among her numerous achievements, she has held many leadership roles at a national level, including being a member of the Board of the American Society of Transplantation, the Executive Committee of the American Transplant Congress, and Chair of Education Committee of the American Society of Transplantation. Most recently, she served as the president of the American Society of Transplantation. In 2016, The American Society of Nephrology elected Dr. Murphy as its newest Councilor. In these positions, Dr. Murphy aims to directly impact patient care and access to healthcare, specifically, advocating for long-term coverage for immunosuppression. In 2018, she became Chair of the Scientfic Advisory Board for Renalytix AI, a company that uses artificial intelligence solutions in collaboration with the Mount Sinai Health System to improve kidney disease detection, management and treatment.
Dr. Murphy is the Principle Investigator of a study, the Genomics of Chronic Renal Allograft Rejection, (GoCar), which aims to investigate the mechanisms leading to the development of transplant glomerulopathy, chronic arteriopathy funded through the NIH/NIAID Genomics Consortium in Transplantation. The GoCar study, recently published in The Lancet, examines gene expression profiles associated with the development of chronic rejection using microarray on protocol biopsies performed over two years following transplantation. In addition, a larger cohort of donor and recipient pairs are being enrolled to identify polymorphic variants of specific immunological genes which confer susceptibility to chronic rejection and the development of donor specific antibodies.
Dr. Murphy's Lab also investigated a systems biology approach to the identification of genetic drivers of fibrosis in the allograft and the potential application to native kidney. Through this mechanism they have identified several novel mediators of fibrosis which are being investigated further in humans and animal models. SHROOM3 is one such gene. An intronic SNP in SHROOM3 increases expression of SHROOM3 and drives fibrosis in human allograft recipients and murine models of CKD. Her research was published in The Journal of Clinical Investigation.
To read more about Dr. Murphy's research, please visit The Murphy Lab.
Clinical Focus
Multi-Disciplinary Training Area
Immunology [IMM]
Education
MB BAO BCh, The Royal College of Surgeons
MD, Royal College of Surgeons-Ireland
MRCPI, The Royal College of Physicians
FRCPI, The Royal College of Physicians
Internship, Internal Medicine
Beaumont Hospital
Fellowship, Nephrology
Beaumont Hospital
Fellowship, Nephrology-Renal
Brigham and Women's Hospital, Harvard Medical School
Language
English
2018
Honorary Doctorate
Royal College of Surgeons in Ireland
2016
The Annual Irish America Healthcare & Life Sciences 50
2016
Elected Councilor
The American Society of Nephrology
2016
Honorary Fellowship
Royal College of Physicians London
2014
Jacobi Medallion
Mount Sinai Health System
2014
Elected Fellow of the American College of Physicians
2007
President Elect
American Society of Transplantation
2005
Executive Committee and Chair 2007
ATC
2004
Councilor-at-Large
American Society of Transplantation
2004
Irene and Dr. Arthur M. Fishberg Professor of Medicine
2004
Member
NIAID/NIH
AITRC Study Section
2003
Chair
American Society of Nephrology
Transplant Advisory Group
2003
Young Investigator Award
Basic Science
American Society of Transplantation
2003
Chair
American Society of Transplantation
Education Committee
2001
Member
American Society of Nephrology
Program Committee
1997
KO8 Award
National Institute of Health
Principle Investigator
The Genomics of Chronic Allograft Rejection (GoCAR)
This study aims to investigate the mechanisms leading to the development of transplant glomerulopathy, chronic arteriopathy funded through the NIH/NIAID Genomics Consortium in Transplantation. The study examines the contribution of the direct and indirect pathways of allorecognition, and the development of de novo donor specific antibodies to this pathologic finding in a large prospective group of renal transplant recipients. The studies is examining the gene expression profile associated with the development of chronic rejection using microarray on protocol biopsies performed over two years following transplantation. In addition, a larger cohort of donor and recipient pairs are being enrolled to identify polymorphic variants of specific immunological genes which confer susceptibility to chronic rejection and the development of donor specific antibodies.
Patients have been enrolled in 5 clinical sites including Mount Sinai, Westmead Hospital Sydney, University Wisconsin – Madison Medical Center, University of Michigan Medical Center, Ann Arbor, and Northwestern Medical Center. The findings of this study will lead to important insights into the pathologic mechanisms mediating chronic allograft loss. Initial finding suggest that differential gene expression on normal 3 month protocol biopsies may be potentially used to immunologically stratify transplant recipients.
Researchers Identify Genes That Predict Damage in Donated Kidneys
From The Lancet: Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study
Genetic Variability and Outcomes in Transplantation
Organ transplantation results in increased life expectancy and lifestyle advantages as compared to all other modalities of kidney replacement therapy. Despite a marked improvement in rejection rates over the last decade, the improvement in long-term allograft survival remains modest. Recent advances from the Human Genome Project have identified numerous regions of genetic variability, both single-nucleotide polymorphisms (SNP's) and microsatellites regions, within genes relevant to transplantation. We have studied polymorphisms in chemokines and their receptor and costimulatory molecules and demonstrated three gene polymorphisms in CTLA-4 including one microsatellite dinucleotide repeat in the 3' untranslated region (3'-UTR) of the final exon (+642 (AT)n), and two SNP's located in the promoter (-318 C/T) and the first exon (+49 A/G) associated with functional effects and the incidence of autoimmune diseases. We have found an association with the (AT)92 and (AT)94 alleles of the +642 (AT)n microsatellite and acute rejection in both liver and kidney recipients. Analysis of CTLA-4 +49A/G demonstrated no association with acute rejection in either kidneys or livers. We have now extended this analysis to include the CTLA4 -318C/T and CD28 +17T/C SNP's for acute rejection and allograft survival. Homozygosity for the G allele of CTLA4 +49A/G significantly reduced 5 and 10-year graft survival, while the CTLA-4 +642(AT)n alleles associated with acute rejection (92, 94 and 100bp) were also associated with decreased graft survival and occurred more frequently in African American. Studies now focus on the relationship between haplotypes, graft survival and acute rejection. These studies form the basis for a larger prospective study in transplant recipients.
Risk factor for Renal Allograft Fibrosis
A systems biology approach to the identification of genetic drivers of fibrosis in the allograft and the potential application to native kidney. Through this mechanism we have identified several novel mediators of fibrosis which are being investigated further in humans and animal models. SHROOM3 is one such gene. An intronic SNP in SHROOM3 increases expression of SHROOM3 and drives fibrosis in human allograft recipients and murine models of CKD.
From JCI: Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Murphy during 2019 and/or 2020. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Regeneron Pharmaceuticals
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- Yale University School of Medicine
Royalty Payments:
- RenalytixAI
Scientific Advisory Board:
- ITB pharma
- Royal College of Surgeons in Ireland
- Veloxis
Service on Board of Directors: Service in a fiduciary capacity, such as an officer or director, for the following companies:
- American Society of Nephrology
- RenalytixAI
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.